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Abstract 
AIM: Blocking effect of leukotriene biosynthesis–zileuton and blocking the effect of phosphodiesterase enzyme–
diprophylline in the treatment of patients with bronchial asthma and bronchial increased reactivity, and tiotropium 
bromide as an antagonist of the muscarinic receptor studied in this work. 
METHODS: Parameters of the lung function are determined with Body plethysmography. The resistance of the 
airways (Raw) was registered and measured was intrathoracic gas volume (ITGV), and specific resistance 
(SRaw) was also calculated. For the research, administered was zileuton (tabl. 600 mg) and diprophylline (tabl. 
150 mg).  
RESULTS: Two days after in-house administration of leukotriene biosynthesis blocker–zileuton (4 x 600 mg 
orally), on the day 3 initial values of patients measured and afterwards administered 1 tablet of zileuton, and again 
measured was Raw and ITGV, after 60, 90 and 120 min. and calculated was SRaw; (p < 0.01). Diprophylline 
administered 7 days at home in a dose of (2 x 150 mg orally), on the day 8 to same patients administered 1 tablet 
of diprophylline, and performed measurements of Raw, ITGV, after 60, 90 and 120 min, and calculated the SRaw 
(p < 0.05). Treatment of the control group with tiotropium bromide - antagonist of the muscarinic receptor (2 inh. x 
0.18 mcg), is effective in removal of the increased bronchomotor tonus, by also causing the significant decrease 
of the resistance (Raw), respectively of the specific resistance (SRaw), (p < 0.05). 
CONCLUSION: Effect of zileuton in blocking of leukotriene biosynthesis is not immediate after oral administration, 
but the effect seen on the third day of cys-LTs’ inhibition, and leukotriene B4 (LTB4) and A4 (LTA4) in patients 
with bronchial reactivity and bronchial asthma, which is expressed with a high significance, (p < 0.01). Blockage of 
phosphodiesterase enzyme–diprophylline decreases the bronchial reactivity, which is expressed with a moderate 
significance, (p < 0.05). 
 
 
 
 
 
 
 
Introduction 
 
Hyperactivity of the airways is manifested with 
acute bronchoconstriction. Recent studies indicate 
that blocking the effect of leukotriene biosynthesis is 
efficient in the treatment of hyperactivity and bronchial 
asthma. Effect of this medication is about the 
treatment of slight and moderate forms of bronchial 
asthma [1]. Effects of cys-LTs’ appears not only 
because of the activation of cys-LT1 receptor.But, 
also through cys-LTs’ which trigger the vascular 
smooth muscle contraction [2] and stimulate activity of 
the P-selectin produced by endothelial cells through 
receptor LT2 [3].  
Inhibitors of 5-lipoxygenase (5LO) and of the 
protein which activate 5LO (5-lipoxygenase activating 
protein–FLAP) such as GSK-2190915 (FLAP-inhibitor) 
acts not only in cysteinyl-leukotrienes but also inhibits 
the creation of LTB4, which can be useful at 
neutrophile asthma [4]. It also inhibits the early and 
late asthmatic reaction during provoking test inhalator 
allergen. It also decreases the number of LTB4 
eosinophils in sputum. 
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Most of the authors agree that medicines 
which block the biosynthesis of leukotriene are the 
first line of asthma therapy, as an efficient alternative 
for reduction of inhaling doses of corticosteroids [5]. 
In the latest medical literature, highest 
importance is attributed to the caffeine, namely its 
capability to block the adenosine receptor. Adenosine 
receptor act through G-protein and that is why the 
possibility of new synthesis and their introduction to 
the specific blocker therapy is intensively studied, 
more powerful to these receptors. Adenosine causes 
contraction of airways smooth muscles and increases 
the release of histamine by mastocyte [6].  
In the isolated preparation of frenicus-
diaphragm, caffeine and theophylline increase the 
contractility of the diaphragm during the direct and 
indirect stimulation. In the isolated preparation of 
frenicus-diaphragm, methylxanthines cause the 
fatigue to be removed. Also, caffeine and theophylline 
remove the tiredness of the diaphragm during chronic 
obstructive pulmonary diseases (COPD). Deemed 
that this effect causes the removal of dyspnoea at the 
severe airways obstruction [7]. 
Inhibitors of phosphodiesterase such as 
diprophylline block the synthesis and secretion of 
inflammatory mediators from many types of cells 
including mastocytes and basophils. This effect of 
diprophylline may be caused as consequence of PDE 
inhibition and can be imitated in largest part with 
medicines that selectively inhibit the isoenzyme PDE4 
[8]. In therapeutic concentration, therapeutic effects of 
diprophylline are related more with its anti-
inflammatory effect rather than with bronchodilation 
effect. However, this remains to be proved. 
Administration of these medicines to patient 
leads to the improvement of symptoms, lung function 
parameters, reduce of medicines usage, less 
aggravated breathing through the night, respectively 
improvement in all parameters necessary in the 
disease control process. They are also administered 
concomitantly with other antiasthmatics, such: 
agonists beta2-adrenergic receptor, corticosteroids, 
and antagonists of the muscarinic receptor, to which 
they have synergist and additive effect [9] [10].  
Inhibitors of phosphodiesterase 4 (PDE4) 
have an immune modulatory effect. In the treatment of 
severe asthma, necessary are many doses which 
cannot be applied due to side effects to the 
gastrointestinal tract [11]. 
Inhalation forms of the medicines can improve 
these deficiencies and their therapeutic index [12]. 
Blocking effect of leukotriene biosynthesis – 
zileuton, orally administered and blocking the effect of 
phosphodiesterase enzyme-diprophylline 
administered in the treatment of patients with 
bronchial asthma and bronchial increased reactivity, 
and tiotropium bromide as an antagonist of the 
muscarinic receptor studied in this work.  
Material and Methods  
 
Examination performed in 14 patients with 
bronchial asthma and increased bronchial reactivity. 
At least 48 hours before the research of bronchial 
reactivity response, patients have not administered 
any of the bronchodilator substances. Examined were 
informed regarding the method of the functional 
pulmonary tests. Patients had asthma, with or without 
associated bronchitis.  
Pulmonary function, composed of 
measurement of vital capacity (VC), forced expiratory 
volume in the first second (FEV1), resistance in the 
airways (Raw) and intrathoracic gas volume (ITGV), 
was defined at the rest. The overall quantity of the 
intrathoracic gas volume (ITGV) was measured with 
the plethysmography method, including non-ventilated 
closed gas. If the residual functional capacity is taken 
from the ITGV, obtained by the plethysmography 
method, we will gain information regarding the 
quantity of closed gas due to a severe obstruction, 
cystic lungs, or pneumothorax. In healthy subjects 
with a normal pulmonary function, the volume of the 
intrathoracic gas is equal to the residual functional 
capacity. From the beta and alpha angles, assisted by 
tables, values of the airways resistance and volume of 
the intrathoracic gas are calculated. From gained 
values, the specific resistance was calculated: 
SRaw = Raw x ITGV 
Raw and the SRaw were taken for analyses. 
Research of the bronchial response to different 
substances was done with the measurement of Raw 
and the SRaw as very sensitive indicators.  
Basic and pulmonary function features 
researched provided in Table 1.  
Table 1: Basic and pulmonary function features 
n Age (yrs) Height (cm) Weight 
(kg) 
VC (%) FEV1 (%) Raw (kPa 
L/s) 
ITGV (L) 
14 45 ± 1.60 177.13 ± 1.5 71.77±0.5 3.41±3.5 3.02±1.26 0.19.5±0.1 3.05±3.05 
 
Zileuton, as a blocker of leukotriene receptor 
(600 mg, tablet) administered per os 2 days in a row 
at home (4 x 600 mg) and on the 3
rd
 day reported to 
the ambulance and measured initial values. One 
tablet administered orally at the ambulance, and 
measured Raw and ITGV after 60, 90 and 120 min. In 
the end, as control, administered was tiotropium 
bromide in the form of an aerosol and a dose of (2 inh. 
x 18 mcg), and Raw and ITGV values were measured 
again, and SRaw was calculated.  
Diprophylline, as a blocker of leukotriene 
receptor, administered in-house for 7 days (2 x 150 
mg) and on the 8
th
 to the same patient administered 1 
tablet of diprophylline, measured Raw and ITGV after 
60, 90 and 120 min., with SRaw that was calculated 
afterwards. As above, the control group was treated 
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with tiotropium bromide-aerosol (antagonist of the 
muscarinic receptor), and after 5 minutes of 
administration, Raw and ITGV values were measured, 
and SRaw was calculated. 
Used was the hypothesis that changes in the 
respiratory system are not important, not related to the 
development of bronchial asthma or other obstructive 
diseases, and not related to allergic manifestation.  
Gained results grouped and analysed. 
Statistic data processing included determination of the 
average values (X), standard deviation (SD), standard 
mistake (SEM).  
Gained results tested with a t-test to ascertain 
significant changes in between examined groups. To 
compare groups, utilised was statistic computer 
software GraphPadInStat III.  
 
 
Results 
 
Results of this research, in patients with 
bronchial asthma, indicate that patients with increased 
bronchial reactivity 2 days after in-house 
administration of zileuton, a blocker of leukotriene 
biosynthesis, at a dose of (2 x 600 mg) reported to the 
ambulance and measured initial values.  
 
Figure 1: Effect of zileuton (p < 0.01), (2 x 600 mg, tablet), and tiotropium 
bromide (p < 0.05), (2 inh. x 18 mcg); in Raw, ITGV and SRaw. 2 days after 
in-house administration of zileuton (4 x 600 mg); (n = 7; X ± SEM) 
 
One tablet administered orally and measured 
the Raw and ITGV again after 60, 90 and 120 min., 
and because of significant leukotriene biosynthesis 
inhibition (p < 0.01) reduced was the increased 
bronchomotor tonus. Diprophylline, as blocker of 
phosphodiesterase enzyme after in-house 
administration for 7 days (2 x 150 mg) and on the 8
th
 
administered 1 tablet of diprophylline, measured Raw 
and ITGV after 60, 90 and 120 min., with SRaw that 
was also calculated; as result of phosphodiesterase 
enzyme blockage (diprophylline), significantly was 
reduced the increased bronchomotor tonus (p < 0.05); 
also, as treatment of the control group with tiotropium 
bromide (2 inh. X 18 mcg), antagonist of the 
muscarinic receptor, which is effective in removal of 
the increased bronchomotor tonus, by causing 
significant decrease of the resistance (Raw), 
respectively of the airways specific resistance (SRaw), 
(p < 0.05). 
 
Figure 2: Effect of diprophylline (p < 0.05), (2 x 150 mg, tablet), and 
tiotropium bromide (p < 0.05), (2 inh. x 18 mcg); in Raw, ITGV and SRaw. 2 
days after in-house administration of diprophylline (n = 7; X ± SEM) 
 
 
 
Discussion 
 
Clinical trials with blocking medicines of 
leukotriene biosynthesis were quite heterogeneous in 
response to the therapy, with patients that can be 
classified in two groups, those “responding” on the 
treatment and those “not responding” to it. For 
patients responding to the treatment with blockers of 
leukotriene receptor, pulmonology institution has 
recognised these medicines as an alternative to 
inhaled steroids, in small doses, to maintain slight 
chronic asthma under control. 
Zileuton, as a blocker of the leukotriene 
biosynthesis, is a powerful selective inhibitor of the 
activity of 5-lipoxygenase and as such inhibits the 
biosynthesis of its products. Consequently, besides 
inhibition of cys-LTs’, zileuton also inhibits the 
biosynthesis of leukotriene B4 (LTB4), which is a 
powerful chemotactic and another eicosanoid too, 
which depend on the synthesis of leukotriene A4 
(LTA4). Theoretically, therapeutic effects of 5-
lipoxygenase should include all those seen at the 
antagonist cys-LT1, but also other effects which 
include inhibition of the LTB4 and other products of 5-
lipoxygenase. It is deemed that LTB4 acts through 
receptor LT1 and LT2, by causing accumulation of 
neutrophils, but their role remains yet unclear [13] 
[14].  
Some clinical trials indicated that blockers of 
the leukotriene biosynthesis have an affinity in the 
reduction of the dose of inhaled steroids necessary to 
control asthma exacerbation [15] [16]. If so, this can 
 Clinical Science 
_______________________________________________________________________________________________________________________________ 
 
_______________________________________________________________________________________________________________________________ 
780                                                                                                                                                                                                https://www.id-press.eu/mjms/index 
 
be quite important, especially in children suffering 
from a more severe asthma. 
Blocking effect of leukotriene biosynthesis-
zileuton, in the treatment of patients with bronchial 
asthma and increased bronchial reactivity in 
comparison to the control group treated with 
tiopentium bromide applied via inhalation (as an 
antagonist of the muscarinic receptor) studied in this 
work. Two days after in-house administration of 
zileuton, and because of significant blockage of 
leukotriene biosynthesis (p < 0.01) decreased was the 
increased bronchomotortonus in patients with 
emphasized reactivity; effect of tiopentium bromide is 
efficient in removal of increased bronchomotor tonus, 
causing significant decrease of the resistance (Raw), 
namely of the specific resistance (SRaw), (p < 0.05).  
Blockers of the leukotriene biosynthesis at 
doses applied 2 days after in-house administration of 
zileuton to the same patient, cause lowering of 
systolic and diastolic blood pressure (BP), but not 
significantly (p > 0.1) [17]. 
Blockers of adenosine receptors and 
inhibitors of PDE can play a role in lung 
bronchodilation effect. Adenosine does not contract 
the isolated smooth muscle of human bronchi directly, 
but when inhaled it acts as powerful 
bronchoconstrictor at asthmatics [18]. Thus, inhibition 
of the adenosine function can contribute to the 
bronchodilation triggered by diprophylline at some 
asthmatics. Inhibition of PDE4 and PDE5 effectively 
relaxes the isolated smooth muscle of human bronchi. 
Thus, seems that inhibition of PDE may contribute to 
the bronchodilation effect of theophylline. Studies 
conducted with methylxanthine enprofylline (3-
propylxanthine), which is studied a lot for asthma 
treatment in Europe, supports the role of PDE 
inhibition in bronchodilation effects of theophylline. 
Regarding bronchodilation, Enprofylline is more 
powerful than theophylline but is less powerful at 
inhibition of largest part of adenosine receptor types. 
The latter is to be carefully interpreted. Activation of 
subtype A2B of adenosine receptor causes some pro-
inflammatory effects, and both theophylline and 
enprofylline are powerful competitive antagonists of 
the A2B adenosine receptor [19] [20]. 
Selective inhibitors of PDE4 are assessed in 
various clinical trials in asthma treatment and chronic 
obstructive pulmonary disease (COPD). In a study, 
cilomilast (Ariflo 15 mg two times a day for 10 weeks) 
significantly reduced infiltration of inflammatory cells, 
which is seen in the bronchial biopsies of patients with 
COPD. Further studies are necessary to determine 
the role of PDE4 inhibitors in asthma and COPD, but 
these medicines are promissory regarding new 
approaches to asthma therapy [21]. 
Our research indicates that due to result of 
inhibition of phosphodiesterase (doxofylline) reduced 
was the significantly increased bronchomotor tonus 
(p<0.05); also, as treatment of the control group with 
tiotropium bromide (antagonist of the muscarinic 
receptor), which is effective in removal of the 
increased bronchomotor tonus, by causing significant 
decrease of the resistance (Raw), respectively of the 
airways specific resistance (SRaw), (p < 0.05). 
Further studies are necessary to determine 
the role of these medicines in moderated and severe 
asthma. Some clinical trials have shown that blockers 
of the leukotriene biosynthesis possess an affinity to 
reduce doses of inhaled steroids necessary to control 
asthma exacerbations [22]. Even though leukotriene 
inhibitors are efficient in the prophylactic treatment of 
slight asthma; their role in the asthma therapy is not 
defined. Most of the clinical trials with these medicines 
studied at the patients with slight asthma, who do not 
administer glucocorticoids. In general, studies show a 
modest, but important improvement to the pulmonary 
function and a decrease of symptoms and asthma 
exacerbation. 
Based on results gained, it can be concluded 
as follows: 
In patients with bronchial asthma and 
emphasised bronchial reactivity, an orally 
administered blocker of leukotriene biosynthesis-
zileuton, 2 times a day (4 x 600 mg), causes 
emphasised and a significant decrease of the specific 
resistance (SRaw) of airways, (p < 0.01). 
Blocker of phosphodiesterase enzyme-
diprophylline, orally administered for 7 days in a row 
at doses of 2 x 150 mg, also causes a significant 
decrease of the specific resistance (SRaw) of airways, 
(p < 0.05). 
Treatment of the control group with tiotropium 
bromide-antagonist of the muscarinic receptor (2 inh. 
x 0.18 mcg), is effective in removal of the increased 
bronchomotor tonus, by causing the significant 
decrease of the resistance (Raw), respectively of the 
specific resistance (SRaw), (p < 0.05).  
Effect of a blocker of leukotriene biosynthesis 
– zileuton, applied to patients with reversible bronchial 
reactivity, is powerful only after two days of the intake, 
causing cys-LTs’ inhibition, and blocking of 
leukotriene B4 (LTB4) and A4 (LTA4) biosynthesis, (p 
< 0.01). 
Results, also indicate that blocker of 
phosphodiesterase enzyme significantly blocks 
connection to the adenosine receptor (p < 0.05), but 
their effect is weaker in the respiratory system rather 
that of the leukotriene biosynthesis blockers. 
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